Canadian and U.S. radiologists may face different regulatory restrictions when it comes to use of ultrasound contrast, but both agree on one thing: the agents have a positive effect on clinical practice, according to studies presented at the RSNA meeting on Monday.
Canadian and U.S. radiologists may face different regulatory restrictions when it comes to use of ultrasound contrast, but both agree on one thing: the agents have a positive effect on clinical practice, according to studies presented at the RSNA meeting on Monday.
Principal investigator Bina Lanka, a medical student at the University of Toronto, assessed the value of CE sonography for diagnosis and management of liver tumors in a tertiary clinical practice. The research team retrospectively reviewed data from 1088 patients collected between July 2003 and December 2005.
Use of CE sonography in this setting bolstered patient management by providing fast, accurate detection of liver masses and resolving uncertain findings by other imaging modalities. The team confirmed that the number of referrals for this type of CE ultrasound exam increased progressively during the two-year study period.
Researchers noted several positive implications of CE ultrasound use:
"Contrast-enhanced sonography has had a very positive impact at our institution," Lanka said.
In a separate study, Dr. Yuko Kono, a radiologist at the University of California, San Diego, recorded results for off-label use of CE sonography in clinical practice between 2000 and 2006. The research team found that although few patients underwent CE sonography studies during this period, its use added critically valuable information in 75% of the cases in which it was used, without increasing risk.
"Ultrasound contrast is useful in many applications and helps clinical practice. We need ultrasound contrast media approval in the U.S.," Kono said.
Contrast sonography helped confirm or characterize liver lesions in 59 patients. It assessed vascular patency in 18, including seven transjugular intrahepatic porto-systemic shunts. It also helped evaluate renal, splenic, and other abdominal abnormalities. In most of these cases, CE sonography replaced inconclusive contrast CT or MR studies, Kono said.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
RSNA 2020: Addressing Healthcare Disparities and Access to Care
December 4th 2020Rich Heller, M.D., with Radiology Partners, and Lucy Spalluto, M.D., with Vanderbilt University School of Medicine, discuss the highlights of their RSNA 2020 session on health disparities, focusing on the underlying factors and challenges radiologists face to providing greater access to care.